Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PGEN

PGEN - Precigen Inc Stock Price, Fair Value and News

$4.47-0.26 (-5.50%)
Market Closed

9/100

PGEN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

9/100

PGEN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$3.81

Target 3M

$4.28

Target 6M

$4.05

PGEN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PGEN Price Action

Last 7 days

0.2%

Last 30 days

0.5%

Last 90 days

10.4%

Trailing 12 Months

252.0%

PGEN RSI Chart

PGEN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PGEN Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

-6.41

Price/Sales (Trailing)

61.63

EV/EBITDA

-10.83

Price/Free Cashflow

-20.92

PGEN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$3.81

Target 3M

$4.28

Target 6M

$4.05

PGEN Fundamentals

PGEN Revenue

Revenue (TTM)

22.1M

PGEN Earnings

Earnings (TTM)

-246.9M

Earnings Growth (Yr)

-510.33%

Earnings Growth (Qtr)

-449.3%

PGEN Profitability

EBT Margin

-579.23%

Return on Equity

-589.63%

Return on Assets

-144.14%

Free Cashflow Yield

-4.78%

PGEN Investor Care

Shares Dilution (1Y)

20.81%

Diluted EPS (TTM)

-1.38

PGEN Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202323.2M22.1M00
202216.3M15.4M28.8M26.9M
202197.9M71.2M51.0M35.3M
202098.0M95.6M100.8M103.2M
2019134.1M121.7M107.5M90.7M
2018217.1M208.0M194.4M151.2M
2017201.2M203.2M200.2M231.2M
2016183.2M190.8M186.4M190.9M
201597.9M131.0M163.2M173.6M
201427.7M32.8M48.0M71.9M
201316.1M20.1M23.2M23.8M
20129.5M10.9M12.3M13.8M
20110008.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Precigen Inc

PGEN
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments, Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and Lactococcus lactis, a food-grade bacterium. Additionally, it provides RheoSwitch Therapeutic System, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
 CEO
 WEBSITEhttps://precigen.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES209

Precigen Inc Frequently Asked Questions

PGEN is the stock ticker symbol of Precigen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Precigen Inc is 1.58 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PGEN's fair value in chart for subscribers.

The fair value guage provides a quick view whether PGEN is over valued or under valued. Whether Precigen Inc is cheap or expensive depends on the assumptions which impact Precigen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PGEN.

As of Wed Jan 28 2026, PGEN's PE ratio (Price to Earnings) is -6.41 and Price to Sales (PS) ratio is 61.63. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PGEN PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Precigen Inc has provided -0.171 (multiply by 100 for percentage) rate of return.